Is it ever safe to stop azole therapy for Coccidioides immitis meningitis?

Daniel H. Dewsnup, John N Galgiani, J. Richard Graybill, Manuel Diaz, Adrian Rendon, Gretchen A. Cloud, David A. Stevens

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Objective: To determine 1) whether patients with coccidioidal meningitis who had achieved remission with oral azole therapy were cured and 2) when oral azole therapy could be discontinued in these patients. Design: Data were gathered on patients with coccidioidal meningitis who had successfully responded to azole therapy in previous clinical trials. Setting: Referral centers, including university, county, and veterans' hospitals and clinics. Patients: 18 patients in whom azole therapy for meningitis had been discontinued, usually because of a presumption of cure. Main Outcome Measures: Clinical and cerebrospinal fluid relapse. Results: 14 of 18 patients (78% [95% CI, 52% to 94%]) had relapse with disseminated disease after discontinuation of therapy, for a total of 1 nonmeningeal and 15 meningeal relapses to date. Relapse occurred both soon and late (range, 0.5 to 30 months) after therapy was discontinued. The characteristics of patients who did not have relapse, including the particular azole used, the duration of therapy, the reason therapy was discontinued, and the cerebrospinal fluid indices before discontinuation, were similar to the characteristics of patients who had relapse. Relapse had serious consequences in some patients; 3 patients died. Conclusion: Our data suggest 1) that disease is only suppressed in patients with meningitis who achieve remission while receiving azole therapy and 2) that discontinuing azole therapy is unsafe. The alternative is lifelong treatment with azoles; this appears to be acceptable, because toxicity is uncommon with triazole therapy, even long-term triazole therapy.

Original languageEnglish (US)
Pages (from-to)305-310
Number of pages6
JournalAnnals of Internal Medicine
Volume124
Issue number3
StatePublished - Feb 1 1996
Externally publishedYes

Fingerprint

Coccidioides
Azoles
Meningitis
Recurrence
Therapeutics
Triazoles
Cerebrospinal Fluid
Veterans Hospitals
County Hospitals

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dewsnup, D. H., Galgiani, J. N., Graybill, J. R., Diaz, M., Rendon, A., Cloud, G. A., & Stevens, D. A. (1996). Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Annals of Internal Medicine, 124(3), 305-310.

Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? / Dewsnup, Daniel H.; Galgiani, John N; Graybill, J. Richard; Diaz, Manuel; Rendon, Adrian; Cloud, Gretchen A.; Stevens, David A.

In: Annals of Internal Medicine, Vol. 124, No. 3, 01.02.1996, p. 305-310.

Research output: Contribution to journalArticle

Dewsnup, DH, Galgiani, JN, Graybill, JR, Diaz, M, Rendon, A, Cloud, GA & Stevens, DA 1996, 'Is it ever safe to stop azole therapy for Coccidioides immitis meningitis?', Annals of Internal Medicine, vol. 124, no. 3, pp. 305-310.
Dewsnup DH, Galgiani JN, Graybill JR, Diaz M, Rendon A, Cloud GA et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Annals of Internal Medicine. 1996 Feb 1;124(3):305-310.
Dewsnup, Daniel H. ; Galgiani, John N ; Graybill, J. Richard ; Diaz, Manuel ; Rendon, Adrian ; Cloud, Gretchen A. ; Stevens, David A. / Is it ever safe to stop azole therapy for Coccidioides immitis meningitis?. In: Annals of Internal Medicine. 1996 ; Vol. 124, No. 3. pp. 305-310.
@article{34d9dca0f1f24faebcc19f8013abbc6a,
title = "Is it ever safe to stop azole therapy for Coccidioides immitis meningitis?",
abstract = "Objective: To determine 1) whether patients with coccidioidal meningitis who had achieved remission with oral azole therapy were cured and 2) when oral azole therapy could be discontinued in these patients. Design: Data were gathered on patients with coccidioidal meningitis who had successfully responded to azole therapy in previous clinical trials. Setting: Referral centers, including university, county, and veterans' hospitals and clinics. Patients: 18 patients in whom azole therapy for meningitis had been discontinued, usually because of a presumption of cure. Main Outcome Measures: Clinical and cerebrospinal fluid relapse. Results: 14 of 18 patients (78{\%} [95{\%} CI, 52{\%} to 94{\%}]) had relapse with disseminated disease after discontinuation of therapy, for a total of 1 nonmeningeal and 15 meningeal relapses to date. Relapse occurred both soon and late (range, 0.5 to 30 months) after therapy was discontinued. The characteristics of patients who did not have relapse, including the particular azole used, the duration of therapy, the reason therapy was discontinued, and the cerebrospinal fluid indices before discontinuation, were similar to the characteristics of patients who had relapse. Relapse had serious consequences in some patients; 3 patients died. Conclusion: Our data suggest 1) that disease is only suppressed in patients with meningitis who achieve remission while receiving azole therapy and 2) that discontinuing azole therapy is unsafe. The alternative is lifelong treatment with azoles; this appears to be acceptable, because toxicity is uncommon with triazole therapy, even long-term triazole therapy.",
author = "Dewsnup, {Daniel H.} and Galgiani, {John N} and Graybill, {J. Richard} and Manuel Diaz and Adrian Rendon and Cloud, {Gretchen A.} and Stevens, {David A.}",
year = "1996",
month = "2",
day = "1",
language = "English (US)",
volume = "124",
pages = "305--310",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Is it ever safe to stop azole therapy for Coccidioides immitis meningitis?

AU - Dewsnup, Daniel H.

AU - Galgiani, John N

AU - Graybill, J. Richard

AU - Diaz, Manuel

AU - Rendon, Adrian

AU - Cloud, Gretchen A.

AU - Stevens, David A.

PY - 1996/2/1

Y1 - 1996/2/1

N2 - Objective: To determine 1) whether patients with coccidioidal meningitis who had achieved remission with oral azole therapy were cured and 2) when oral azole therapy could be discontinued in these patients. Design: Data were gathered on patients with coccidioidal meningitis who had successfully responded to azole therapy in previous clinical trials. Setting: Referral centers, including university, county, and veterans' hospitals and clinics. Patients: 18 patients in whom azole therapy for meningitis had been discontinued, usually because of a presumption of cure. Main Outcome Measures: Clinical and cerebrospinal fluid relapse. Results: 14 of 18 patients (78% [95% CI, 52% to 94%]) had relapse with disseminated disease after discontinuation of therapy, for a total of 1 nonmeningeal and 15 meningeal relapses to date. Relapse occurred both soon and late (range, 0.5 to 30 months) after therapy was discontinued. The characteristics of patients who did not have relapse, including the particular azole used, the duration of therapy, the reason therapy was discontinued, and the cerebrospinal fluid indices before discontinuation, were similar to the characteristics of patients who had relapse. Relapse had serious consequences in some patients; 3 patients died. Conclusion: Our data suggest 1) that disease is only suppressed in patients with meningitis who achieve remission while receiving azole therapy and 2) that discontinuing azole therapy is unsafe. The alternative is lifelong treatment with azoles; this appears to be acceptable, because toxicity is uncommon with triazole therapy, even long-term triazole therapy.

AB - Objective: To determine 1) whether patients with coccidioidal meningitis who had achieved remission with oral azole therapy were cured and 2) when oral azole therapy could be discontinued in these patients. Design: Data were gathered on patients with coccidioidal meningitis who had successfully responded to azole therapy in previous clinical trials. Setting: Referral centers, including university, county, and veterans' hospitals and clinics. Patients: 18 patients in whom azole therapy for meningitis had been discontinued, usually because of a presumption of cure. Main Outcome Measures: Clinical and cerebrospinal fluid relapse. Results: 14 of 18 patients (78% [95% CI, 52% to 94%]) had relapse with disseminated disease after discontinuation of therapy, for a total of 1 nonmeningeal and 15 meningeal relapses to date. Relapse occurred both soon and late (range, 0.5 to 30 months) after therapy was discontinued. The characteristics of patients who did not have relapse, including the particular azole used, the duration of therapy, the reason therapy was discontinued, and the cerebrospinal fluid indices before discontinuation, were similar to the characteristics of patients who had relapse. Relapse had serious consequences in some patients; 3 patients died. Conclusion: Our data suggest 1) that disease is only suppressed in patients with meningitis who achieve remission while receiving azole therapy and 2) that discontinuing azole therapy is unsafe. The alternative is lifelong treatment with azoles; this appears to be acceptable, because toxicity is uncommon with triazole therapy, even long-term triazole therapy.

UR - http://www.scopus.com/inward/record.url?scp=0030022888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030022888&partnerID=8YFLogxK

M3 - Article

C2 - 8554225

AN - SCOPUS:0030022888

VL - 124

SP - 305

EP - 310

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -